Form 4: AnaptysBio CFO Dennis Mulroy Sells Shares Under 10b5-1 Plan

AnaptysBio's CFO, Dennis Mulroy, sold 1,500 shares of common stock at $23.72 per share on May 22, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Dennis Mulroy, the CFO of AnaptysBio, Inc., reported a transaction involving the company's common stock.
• On May 22, 2024, Mulroy sold 1,500 shares of common stock at a price of $23.72 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 26, 2023.
• Following the transaction, Mulroy beneficially owns 964 shares of AnaptysBio common stock, which includes shares acquired through the Employee Stock Purchase Plan up to May 15, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine stock sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning. The use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management.
• The use of a 10b5-1 plan is a common practice to ensure compliance with insider trading regulations, similar to practices at companies like Regeneron and Incyte.
• The amount of shares sold is relatively small compared to the total outstanding shares of AnaptysBio, and is not necessarily indicative of a negative outlook.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small volume of shares sold.
• The transaction is unlikely to significantly affect employees, customers, suppliers, or creditors.

Key Dates